Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on mupirocin resistance

J A Poupard1

  • 1SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA.

Journal of Chemotherapy (Florence, Italy)
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Mupirocin resistance in staphylococci is increasing, particularly in dermatology patients. New testing methods may help track resistance rates in nasal bacteria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study.

International journal of antimicrobial agents·2004
Same author

Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study.

International journal of antimicrobial agents·2003
Same author

Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2003
Same author

The growth and survivability of Streptococcus pneumoniae clinical isolates subjected to various environmental conditions.

Diagnostic microbiology and infectious disease·2003
Same author

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2002
Same author

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.

Diagnostic microbiology and infectious disease·2001
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

Area of Science:

  • Microbiology
  • Pharmacology

Background:

  • Mupirocin targets bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
  • Staphylococcal resistance to mupirocin presents as low-level (mutational) or high-level (plasmid-mediated).
  • Nasal mupirocin formulations for eradication raise concerns regarding established resistance breakpoints.

Purpose of the Study:

  • To review the emergence and mechanisms of staphylococcal resistance to mupirocin.
  • To discuss the implications of nasal mupirocin use on resistance development.
  • To highlight the need for accurate resistance monitoring in staphylococci.

Main Methods:

  • Literature review of mupirocin resistance in staphylococci.
  • Analysis of resistance mechanisms (mutational vs. plasmid-mediated).

Related Experiment Videos

  • Discussion of clinical implications and diagnostic advancements.

    • Main Results:

    • Mupirocin resistance in staphylococci, initially rare, is increasingly reported, especially in dermatology patients.
    • Low-level resistance arises from spontaneous mutations; high-level resistance is plasmid-mediated.
    • The efficacy of current breakpoints is questioned due to high-concentration nasal applications.

    Conclusions:

    • Emerging mupirocin resistance in staphylococci necessitates careful monitoring.
    • The E test and screening disks may improve the assessment of resistance rates in nasal isolates.
    • Understanding resistance patterns is crucial for effective topical antibiotic use.